Trial Profile
A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Oct 2020 Status changed from recruiting to discontinued.
- 31 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2021.
- 31 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2021.